Ukwiranye cyane na Tirzepatide cyangwa Retatrutide?

Iyi ngingo izagufasha guhitamo imwe ikwiranye no gusubiza ibibazo bikurikira:

1.Ni irihe tandukaniro riri hagati ya tirzepatide na retatrutide?

2.Ni izihe nyungu za tirzepatide?

3.Ni izihe nyungu za retatrutide?

4.Gereranya Inyungu za Retatrutide na Tirzepatide

Ni irihe tandukaniro riri hagati ya tirzepatide na retatrutide?

Itandukaniro nyamukuru hagati ya tirzepatide na retatrutide iri mumiterere yabyo.Tirzepatide ni ihuriro ryibintu bitatu bikora - liraglutide, glucagon isa na peptide-1 agonist (GLP-1);analogue ya oxyntomoduline;na GLP-2 analogue.Retarutide, kurundi ruhande, igizwe nikintu kimwe gikora - exenatide, ikindi GLP-1 ikabije cyane muri pancreas.Iyi miti yombi ikoreshwa mu gucunga diyabete yo mu bwoko bwa 2 mu kongera umusaruro wa insuline no kugabanya urugero rwa glucose mu maraso.Nyamara, retarutide kandi yerekanwe kugabanya ubushake bwo kurya kuruta tirzepatide yonyine kubera ingaruka zayo kuri hormone zigira inzara no guhaga.Nkibyo, irashobora gukoreshwa murwego rwo guhuza uburyo bwo gucunga ibiro kubantu barwaye diyabete bafite umubyibuho ukabije cyangwa umubyibuho ukabije.

Ni izihe nyungu za tirzepatide?

①Kunoza igenzura rya glycemic na A1C urwego, biganisha kubuzima bwiza muri rusange

Tirzepatide, glucagon isa na peptide 1 reseptor agonist na GLP-1 / glucose iterwa na insulineotropique polypeptide (GIP) ebyiri agonist, ni uburyo bushya bwo kuvura diyabete yo mu bwoko bwa 2.Byagaragaye ko bifite akamaro kuruta retatrutide mugutezimbere igenzura rya glycemic na A1C.Mu bigeragezo bivura, tirzepatide yajyanye no kugabanuka cyane kurwego rwa A1C mu byumweru 12 ugereranije na retatrutide (-2.3% vs -1.8%), biganisha ku buzima bwiza muri rusange ku barwayi.

②Kugabanya ibyago byo kurwara umutima nimiyoboro y'amaraso nko gutera umutima no guhagarara k'umutima

Tirzepatide itanga inyungu zitandukanye kubantu bashobora guhura nibibazo byumutima nimiyoboro yimitsi nkumutima ndetse nubwonko.Ubushakashatsi bwakozwe mu mwaka wa 2019 bwasohotse mu kinyamakuru The Lancet bwerekanye ko abantu bafata tirzepatide bafite ibyago bike byo kwandura indwara zikomeye z'umutima n'imitsi (MACE) ugereranije n'abafata retatrutide.Ibi byari bikubiyemo kugabanuka kwa 35% muri MACE ugereranije na retatrutide, yerekanaga ko nta tandukaniro rikomeye rigira ku ngaruka z'umutima.Mu gihe cy’ubushakashatsi, abashakashatsi babonye ko abarwayi bafata tirzepatide bahura n’igipimo cyo hasi cy’indwara zifata imitsi y’imitsi, infirasiyo ya myocardial, kunanirwa k'umutima ndetse no guhagarara k'umutima kurusha abo mu itsinda rya retatrutide.Byongeye kandi, abitabiriye gufata tirzepatide bavuze kandi ko urwego rwo kugenzura isukari mu maraso rwiyongereye ndetse no kwiyongera ibiro ugereranije n’abafata retatrutide.Hanyuma, birakwiye ko tumenya ko abantu bafata tirzepatide batakingiwe MACE gusa ahubwo banagabanutse kurwego rwa HbA1c (ikimenyetso cyerekana diyabete yamara igihe kirekire) hamwe nijanisha ryibinure mumubiri ugereranije nurwego rwibanze.Ubwanyuma, ibisubizo byerekana ubushobozi bwa tirzepatide kugirango igabanye ibintu byumutima nimiyoboro y'amaraso bijyana na diyabete yo mu bwoko bwa 2 kandi bitange inyungu zinyongera zijyanye nimiterere yumubiri.

Uburemere bwumubiri ugereranije na retatrutide, bushobora gufasha kugabanya ibyago byindwara ziterwa n'umubyibuho ukabije
Tirzepatide ifite inyungu nyinshi ugereranije na retatrutide, cyane cyane kubijyanye n'uburemere bw'umubiri.Ubushakashatsi bwerekanye ko tirzepatide ishobora gutuma igabanuka ryinshi ryibiro byumubiri kuruta retatrutide mugihe kirekire.Ibi birashobora guterwa nubushobozi bwayo bwo gukangura ibikorwa bya GLP-1 no guteza imbere guhaga.Byongeye kandi, tirzepatide yasanze igabanya amavuta yo munda neza kuruta retatrutide, ishobora gufasha kugabanya ibyago byo kurwara diyabete, indwara zifata umutima ndetse nizindi ndwara ziterwa n'umubyibuho ukabije.Byongeye kandi, tirzepatide yerekanwe kugabanya isukari mu maraso neza kuruta retatrutide.Izi ngaruka zahujwe zirashobora kuzamura ibisubizo byubuzima muri rusange bijyanye n'umubyibuho ukabije no gukora nabi metabolike.

③Kongera ingufu zingufu kubera glucose metabolism

Kimwe mu byiza byingenzi byo gufata tirzepatide nubushobozi bwayo bwo kongera ingufu bitewe na glucose metabolism.Ni ukubera ko GLP1 reseptor agonist nka tirzepatide ikora mukubyutsa irekurwa rya insuline hasubijwe isukari nyinshi mumaraso.Mu kongera umusaruro wa insuline no kunoza metabolisme ya glucose, umubiri urashobora gukoresha glucose nyinshi kuri lisansi kandi ibyo bishobora gutuma ingufu ziyongera.Byongeye kandi, GLP1 reseptor agonist irashobora kandi kugabanya ubushake bwo kurya, bigatuma kugabanuka kwifunguro bigabanuka no gucunga neza ibiro.

Ni izihe nyungu za retatrutide?

Retatrutideni imiti ikora inshinge ndende ikoreshwa mu kuvura diyabete yo mu bwoko bwa 2.Byemejwe n’ikigo cy’Amerika gishinzwe ibiryo n’ibiyobyabwenge (FDA) kubwiyi ntego.Inyungu za retatrutide ni nyinshi, bigatuma ihitamo neza muyindi miti ya diyabete.

Kubatangiye, retatrutide ikora vuba iyo imaze guterwa kandi ingaruka zayo zirashobora kugaragara mumasaha 24 yubuyobozi.Ibi bituma byihuta cyane kurenza izindi inshinge zimara igihe kirekire nka tirzepatide, zishobora gufata ibyumweru byinshi mbere yuko ingaruka zigaragara zigaragara mubipimo by'isukari mu maraso.
Byongeye kandi, ubushakashatsi bwerekanye ko retatrutide igira akamaro mukugabanya urugero rwa A1C kubantu barwaye diyabete yo mu bwoko bwa 2 iyo ifashwe nimirire no guhindura imyitozo.Igeragezwa rya Clinical ryerekanye kandi ko retatrutide ifasha kugabanya glucose yisonzesha no kugenzura glycemic muri rusange kubakoresha ugereranije na placebo.Rimwe na rimwe, abantu batagize inyungu ku miti ya diyabete yo mu kanwa bagize ibisubizo byiza hamwe no kuvura retatrutide.

Hanyuma, kimwe mubyiza byingenzi bya retatrutide nuburyo bworoshye bwo kuyobora;bisaba inshinge imwe gusa mucyumweru aho guterwa inshuro nyinshi nkizindi miti myinshi ivura diyabete.Ibi birashobora gutuma kwita kuri diyabete yawe byoroha kandi bigafasha kunoza kubahiriza gahunda yo kuvura mugihe runaka.

Kugereranya Inyungu za Retatrutide na Tirzepatide

Ku bijyanye no gukora neza, retatrutide yerekanwe kugabanya urwego rwa HbA1c 1,9-2.4%, ugereranije na Tirzepatide igabanya urwego rwa HbA1c 1.5-2%.Imiti yombi nayo igira ingaruka zisa, nko kugira isesemi no kubabara umutwe.Nyamara, abantu bamwe bashobora gusanga bahura ningaruka nke hamwe na Retatrutide kuruta Tirzepatide bitewe nibisabwa bike.

Ku bijyanye n'umutekano, retarutide muri rusange yihanganirwa neza iyo ikoreshejwe kumupanga wasabwe kandi ntabwo byongera ibyago byo kurwara hypoglycemia cyangwa gutera ibiro nkuko ubundi buryo bwo kuvura diyabete bushobora.Kurundi ruhande, Tirzepatide itwara ibyago byinshi byo gutera inshinge bitewe nubunini bwayo.Byongeye kandi, iyo ifashwe kurenza urugero irashobora gutera hypoglycemia ikabije no kwiyongera ibiro.

Muri make, retarutide na tirzepatide nuburyo bwiza bwo kuyobora diyabete yo mu bwoko bwa 2 ariko imwe irashobora kuba nziza kubarwayi bamwe bitewe nibyifuzo byabo.Retarutide itanga efficacy nziza hamwe ningaruka nkeya mugihe nayo ifite umutekano mukigero cyasabwe;icyakora, Tirzepatide irashobora gutanga kugabanuka kurwego rwa HbA1c ariko irashobora kandi guteza ibyago byinshi byingaruka zikomeye niba bidakoreshejwe neza.Ubwanyuma, ni ngombwa kugisha inama muganga wawe kugirango uhitemo uburyo bwo kuvura bwiza kuri wewe ukurikije ibihe byihariye n'intego z'ubuzima.

Tangira tirzepatide yawe na semaglutide ivura LianFu